ABCB1 and cancer: Moreover, the multi-kinase inhibitor sorafenib (BAY 43-9006) was reported to decrease the mRNA levels of ABCB1 and ABCC1-3 in hepatocellular carcinoma (HCC), suggesting the involvement of the RAF/MEK/ERK pathway in the regulation of multidrug resistant cancer cells [58].